Start Your Search
MA02 - Miscellaneous Topics in the Management of Early Stage Lung Cancer (ID 116)
- Event: WCLC 2019
- Type: Mini Oral Session
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 1
- Now Available
- Moderators:Mireia Serra-Mitjans, Thomas A. D'Amico
- Coordinates: 9/08/2019, 10:30 - 12:00, Interlaken (1988)
MA02.11 - Adjuvant Chemotherapy Following SBRT for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Older Patients (Now Available) (ID 1981)
10:30 - 12:00 | Author(s): Lynette Smith
Adjuvant chemotherapy following surgery has been shown to be beneficial in NSCLC >4 cm in size, regardless of age. We have recently shown that adjuvant chemotherapy improves overall survival following stereotactic body radiotherapy (SBRT) in patients with tumors ≥4 cm in size. We aim to evaluate the role of adjuvant chemotherapy following SBRT in older patients (>70 years) with early stage NSCLC.Method
Patients (>70 years) diagnosed with clinical stages I-II NSCLC (AJCC 7th Edition) from 2004 to 2013, who received SBRT, were identified using the National Cancer Database (n=7,934). The Kaplan-Meier method was used to estimate overall survival (OS) distributions and the log-rank test was used to compare distributions by treatment strategy. Clinical stages I and II were subdivided according to the TNM staging and log-rank tests was used to compare survival distributions by treatment strategy within each subgroup.Result
There were 3991 male patients (50.3%), and 6219 (78.4%) had stage I disease. Among stage I patients, 670 (10.8%) received adjuvant chemotherapy (defined as chemotherapy within 90 days of completion of SBRT), compared to 742 stage II patients (43.3%) received adjuvant chemotherapy. Median OS was better with SBRT in patients with stage I disease (25.2 vs. 19.9 months; p<0.001); while patients with stage II NSCLC had better OS with SBRT + chemotherapy (19.9 vs. 14.6 months; p<0.001). On multivariate analysis, after adjusting for age, gender and facility type, patients with stage I NSCLC who received SBRT alone had better overall survival [HR for death: 0.79 (95% CI, 0.73, 0.87)]. SBRT alone was associated with an increased risk of death in patients with stage II disease [HR: 1.37 (95% CI, 1.23, 1.53). When patients with N0 disease were evaluated based on tumor size, those with tumors ≥4 cm had better OS with SBRT + chemotherapy (18.5 vs. 15.5 months; p=0.003). In contrast, patients with tumors <4 cm did better with SBRT alone (median OS of 24.1 vs. 20.3 months; p<0.001)Conclusion
Adjuvant chemotherapy following SBRT is associated with improved OS in patients >70 years of age and tumors ≥4 cm in size or lymph node involvement.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.